A

Alpha Cognition Inc
XTSX:ACOG

Watchlist Manager
Alpha Cognition Inc
XTSX:ACOG
Watchlist
Price: 0.24 CAD Market Closed
Market Cap: 9.9m CAD

Alpha Cognition Inc
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Alpha Cognition Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
A
Alpha Cognition Inc
XTSX:ACOG
Total Current Assets
$2.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Total Current Assets
$33m
CAGR 3-Years
-25%
CAGR 5-Years
-14%
CAGR 10-Years
6%
Repare Therapeutics Inc
NASDAQ:RPTX
Total Current Assets
$124.4m
CAGR 3-Years
-32%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Current Assets
$438.7m
CAGR 3-Years
-2%
CAGR 5-Years
2%
CAGR 10-Years
35%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Total Current Assets
$480.1m
CAGR 3-Years
-10%
CAGR 5-Years
20%
CAGR 10-Years
22%
Spectral Medical Inc
TSX:EDT
Total Current Assets
CA$7.3m
CAGR 3-Years
39%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
No Stocks Found

Alpha Cognition Inc
Glance View

Market Cap
9.9m CAD
Industry
Biotechnology

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.

ACOG Intrinsic Value
Not Available
A

See Also

What is Alpha Cognition Inc's Total Current Assets?
Total Current Assets
12.2m USD

Based on the financial report for Dec 31, 2021, Alpha Cognition Inc's Total Current Assets amounts to 12.2m USD.

What is Alpha Cognition Inc's Total Current Assets growth rate?
Total Current Assets CAGR 1Y
58%

Over the last year, the Total Current Assets growth was 58%.

Back to Top